- Home
- AENT vs VYGR Comparison
AENT vs VYGR Comparison
Compare AENT & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- VYGR
- Stock Information
- Founded
- AENT 1990
- VYGR 2013
- Country
- AENT United States
- VYGR United States
- Employees
- AENT N/A
- VYGR N/A
- Industry
- AENT Durable Goods
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- VYGR Health Care
- Exchange
- AENT Nasdaq
- VYGR Nasdaq
- Market Cap
- AENT 141.2M
- VYGR 156.0M
- IPO Year
- AENT N/A
- VYGR 2015
- Fundamental
- Price
- AENT $3.54
- VYGR $3.35
- Analyst Decision
- AENT
- VYGR Strong Buy
- Analyst Count
- AENT 0
- VYGR 8
- Target Price
- AENT N/A
- VYGR $14.33
- AVG Volume (30 Days)
- AENT 28.4K
- VYGR 694.1K
- Earning Date
- AENT 05-15-2025
- VYGR 05-06-2025
- Dividend Yield
- AENT N/A
- VYGR N/A
- EPS Growth
- AENT N/A
- VYGR N/A
- EPS
- AENT 0.23
- VYGR N/A
- Revenue
- AENT $1,072,641,000.00
- VYGR $66,958,000.00
- Revenue This Year
- AENT $4.77
- VYGR N/A
- Revenue Next Year
- AENT N/A
- VYGR $45.34
- P/E Ratio
- AENT $15.66
- VYGR N/A
- Revenue Growth
- AENT N/A
- VYGR N/A
- 52 Week Low
- AENT $1.10
- VYGR $2.65
- 52 Week High
- AENT $11.57
- VYGR $9.55
- Technical
- Relative Strength Index (RSI)
- AENT 63.81
- VYGR 53.26
- Support Level
- AENT $3.19
- VYGR $3.23
- Resistance Level
- AENT $3.68
- VYGR $3.64
- Average True Range (ATR)
- AENT 0.32
- VYGR 0.24
- MACD
- AENT 0.11
- VYGR 0.06
- Stochastic Oscillator
- AENT 76.74
- VYGR 64.81
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.